AMGEN INC is 27.0x more valuable than Kymera Therapeutics, Inc. by market capitalization ($191.70 B vs $7.09 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KYMR | AMGN |
|---|---|---|
| Market cap | $7.09 B | $191.70 B |
| US-listed rank | #1167 | #79 |
| Revenue (latest FY) | $39.21M | $36.75B |
| Net income (latest FY) | $311.35M | $7.71B |
| Net margin | 794.0% | 21.0% |
| P/E (trailing FY) | 22.8 | 24.9 |
| SEC filings | 575 | 1,011 |
AMGEN INC is 27.0x more valuable than Kymera Therapeutics, Inc. by market capitalization ($191.70 B vs $7.09 B).
In their latest fiscal years, Kymera Therapeutics, Inc. reported $39.21M in revenue while AMGEN INC reported $36.75B.
Full pages: Kymera Therapeutics, Inc. and AMGEN INC, or browse the full rankings.